AUS
NZ
UK
CA
USA
IND
Highlights:
Genflow Biosciences secures over €4 million in non-dilutive financial support from the Wallonia region for GF-1002 development.
The funding will facilitate the advancement of GF-1002, a gene therapy aimed at treating Metabolic Associated Steatohepatitis (MASH).
This financial support underscores the recognition of Genflow’s innovative approach to gene therapy within the longevity research sector.
Genflow Biosciences Plc (LSE:GENF) has announced the receipt of €4,026,525 in non-dilutive financial support from the Wallonia region, aimed at furthering the development of its lead gene therapy, GF-1002. This therapy targets Metabolic Associated Steatohepatitis (MASH), a severe liver disease with limited treatment options. The funding consists of a non-reimbursable research grant covering a significant portion of research costs and a recoverable advance that will be repaid upon the commercialization of GF-1002.
This financial backing is set to support three years of development activities for GF-1002, with the initial funds expected to serve as working capital. Genflow remains dedicated to securing additional funding to ensure the completion of its project over the next three years.
The acquisition of this funding represents a pivotal moment for Genflow, enhancing its capacity to advance clinical trials for GF-1002. The therapy employs a novel mechanism involving a centenarian variant of the SIRT6 gene, which has shown promising preclinical results in combating MASH, the most prevalent chronic liver disease without effective treatments available.
Dr. Eric Leire, CEO of Genflow, expressed gratitude for the financial support from the Wallonia region, highlighting its significance as validation of the company’s research and development initiatives. The support will bolster Genflow’s position in the evolving landscape of gene therapy and longevity research.
As Genflow moves forward, updates on the progress of GF-1002 will be communicated to stakeholders and the public. The company is committed to enhancing the understanding and treatment of age-related diseases, thereby addressing the challenges posed by an aging global population.
